Insider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Insider Sells $1,500,000.00 in Stock
Insider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Insider Sells $1,500,000.00 in Stock
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) insider Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now directly owns 8,397 shares of the company's stock, valued at approximately $251,910. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
BioXcel治療公司(納斯達克:BTAI-GET評級)內部人士Frank Yocca在1月20日(星期五)的一筆交易中出售了50,000股BioXcel治療公司的股票。這隻股票的平均售價為30.00美元,總價值為1500,000.00美元。交易完成後,這位內部人士現在直接持有該公司8,397股股票,價值約251,910美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過此超鏈接.
BioXcel Therapeutics Stock Up 2.8 %
BioXcel治療公司股票上漲2.8%
Shares of NASDAQ:BTAI opened at $32.01 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 10.28 and a current ratio of 10.34. BioXcel Therapeutics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.96. The stock has a market capitalization of $896.98 million, a P/E ratio of -6.55 and a beta of 1.16. The stock has a 50-day simple moving average of $21.69 and a 200-day simple moving average of $16.43.
納斯達克:北泰週五開盤報32.01美元。該公司的負債權益比率為0.72,速動比率為10.28,流動比率為10.34。BioXcel治療公司的一年低點為8.80美元,一年高位為32.96美元。該股市值為8.9698億美元,市盈率為-6.55,貝塔係數為1.16。該股的50日簡單移動均線切入位為21.69美元,200日簡單移動均線切入位為16.43美元。
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.15). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.05 million. Equities analysts forecast that BioXcel Therapeutics, Inc. will post -5.37 earnings per share for the current year.
BioXcel治療公司(納斯達克代碼:BTAI-GET Rating)最近一次發佈財報是在11月10日星期四。該公司公佈本季度每股收益(EPS)為1.49美元,低於分析師一致預期的1.34美元和0.15美元。該公司本季度營收為14萬美元,而分析師預期為305萬美元。股票分析師預測,BioXcel治療公司本年度每股收益將達到5.37美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Hedge Funds Weigh In On BioXcel Therapeutics
對衝基金入股BioXcel治療公司
A number of institutional investors and hedge funds have recently bought and sold shares of BTAI. Millennium Management LLC boosted its holdings in BioXcel Therapeutics by 872.6% in the 2nd quarter. Millennium Management LLC now owns 188,548 shares of the company's stock worth $2,489,000 after acquiring an additional 169,163 shares during the period. Nuveen Asset Management LLC raised its position in shares of BioXcel Therapeutics by 95.5% in the 3rd quarter. Nuveen Asset Management LLC now owns 217,624 shares of the company's stock valued at $2,572,000 after purchasing an additional 106,314 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of BioXcel Therapeutics by 330.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 125,280 shares of the company's stock valued at $2,620,000 after purchasing an additional 96,180 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of BioXcel Therapeutics by 569.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 91,039 shares of the company's stock valued at $1,202,000 after purchasing an additional 77,449 shares in the last quarter. Finally, State Street Corp raised its position in shares of BioXcel Therapeutics by 4.1% during the 1st quarter. State Street Corp now owns 1,400,753 shares of the company's stock valued at $29,290,000 after acquiring an additional 55,657 shares in the last quarter. Hedge funds and other institutional investors own 42.35% of the company's stock.
多家機構投資者和對衝基金最近買賣了北泰的股票。千禧管理有限責任公司在第二季度增持了872.6%的BioXcel治療公司的股份。Millennium Management LLC現在擁有188,548股該公司的股票,價值2,489,000美元,在此期間又購買了169,163股。Nuveen Asset Management LLC在第三季度將其在BioXcel Treateutics的股票頭寸提高了95.5%。Nuveen Asset Management LLC在上個季度額外購買了106,314股票後,現在擁有217,624股該公司股票,價值2,572,000美元。Dimension Fund Advisors LP在第一季度將其在BioXcel Treateutics的股票頭寸提高了330.5%。Dimension Fund Advisors LP現在擁有125,280股該公司的股票,價值2,620,000美元,上個季度又購買了96,180股。Cubist Systems Strategy LLC在第二季度將其在BioXcel治療公司的股票持有量提高了569.9%。Cubist Systems Strategy LLC在上個季度又購買了77,449股後,現在擁有91,039股該公司股票,價值1,202,000美元。最後,道富集團在第一季度將其在BioXcel治療公司的股票頭寸提高了4.1%。道富銀行目前持有1,400,753股該公司股票,價值29,29萬美元,上一季度又收購了55,657股。對衝基金和其他機構投資者持有該公司42.35%的股票。
About BioXcel Therapeutics
關於BioXcel治療公司
(Get Rating)
(獲取評級)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
BioXcel治療公司是一家商業階段的生物製藥公司,利用人工智能方法開發神經科學和免疫腫瘤學的變革性藥物。該公司的藥物再創新方法利用現有的批准藥物和/或臨牀驗證的候選產品,以及大數據和專有機器學習算法來識別新的治療指數。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 免費獲取StockNews.com關於BioXcel治療(BTAI)的研究報告
- 石油服務公司NOV有足夠的能量維持漲勢嗎?
- Shopify Clears杯柄基地:勢頭還能持續嗎?
- 雪佛龍以750億美元的股票回購取悦股東
- 電子商務的未來:分析和新數據
- 列維·施特勞斯非常適合收益型投資者
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受BioXcel治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioXcel治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。